Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to $1.32B

In-house counsel for clinical-stage biotechs and pharmaceutical acquirers must track this deal’s concurrent asset spinout structure, which establishes a new precedent for partial carveout terms that will shape future biotech M&A negotiation and integration planning.